https://www.protokinetix.com/investors/pktx-investordeck-june2019.pdf

https://seekingalpha.com/instablog/47797823-melikemsmallstocks/5296806-pktx-life-changing-science-life-changing-stock 


PKTX - A Life Changing Science And A Life Changing Stock 
Apr. 25, 2019

 ProtoKinetix, Incorporated (PKTX), Includes: CSBR 

Summary 

PKTX is where CSBR was 3 years ago. 

PKTX's AAGP molecule is life changing. 

Data is coming. With that comes higher stock price. 

Those of you who have been following me the last few years, because of my call on Champions Oncology, CSBR, know that I have been predicting that ProtoKinetix PKTX is destined to be my next CSBR. The dynamics of each company and their respective stocks have parallels that can not go unnoticed. 

For years CSBR had an incredible technology that the market had just not taken notice of. In 2014, 2015 and much of 2016 CSBR essentially traded by appointment and posted many zero volume days. Even a reverse split and an uplist to NASDAQ didn’t wake the stock up. Then around the 3rd quarter of 2016, the market finally took notice and we saw CSBR go from the high 1-dollar range to as high as $15 and some days trading several millions of dollars in volume. Why the big difference? Sure, they had some wins, they raised some money, landed a contract, increased revenues and brought on an IR firm, but at the end of the day, what really happened is, the market finally realized what they were all about. The market is not always efficient. Many great companies go unnoticed for years while many companies that are garbage enjoy the benefit of liquidity and over inflated market caps…dot com bubble, cryptocurrency, tulip bulb mania etc. 

First, a little bit about ProtoKinetix. OTCQB:PKTX. ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. For those of you that are not biochemists or hold a PHD in immunology, let me simplify what this means. Very simply put, their AAGP molecule: 

Is an anti-aging molecule 
Increases cell survivability 
Encourages cell growth 
Increases cell viability 
Improves cell functionality 

Why is this important? Because the use of the AAGP molecule can be used to improve treatments of nearly every disease known to man. I know…that’s a big deal. 

They began their first human trials in 2017. The trial is for the treatment of Type 1 diabetes with pancreatic islet transplants. The addition of AAGP to the transplant should increase the life of the islet, thereby increasing the success of the transplant. 

AAGP is currently being tested or soon to be tested in the following: 

Kidney Ischemia 

Ischemia is a condition that occurs when blood flow to cells, tissues or organs is severely restricted. This condition can affect any part of the human body. When this happens, cell death and organ damage follows rapidly. Ischemia is a major cause of kidney damage, heart attacks and strokes. Testing will determine whether AAGP™ can reduce the inflammatory response that causes cell damage and organ failure that occurs during an ischemic attack. 

Normothermic Liver Perfusion 

Normothermic (body temperature), ex vivo (outside the body) liver perfusion (method of irrigation) is a therapy to livers outside of the body before transplantation. Again, simply put, AAGP, will keep the harvested organ viable longer. This can apply to any organ of the body. A true game changer for organ transplants. 

Retinal Cell Replacement 

Use of AAGP will improve the survival of stem cells that are currently being used in human trials to treat retinal blindness. Studies have already been completed at the University of British Columbia and showed dramatic improvement on cell survivability and viability, functionality with the addition of AAGP. 

Monoclonal Antibody Production 

Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell, these are used in the rapidly growing field of immunotherapy. Monoclonal antibodies are currently being used to treat Cancer, Rheumatoid Arthritis, Multiple Sclerosis, Cardiovascular Disease, Systemic Lupus Erythematosus, Crohn's Disease, Ulcerative Colitis, Psoriasis, Transplant Rejection, and several more conditions. 

By adding AAGP will lead to a dramatic decrease in the cost of production of monoclonal antibody medicines. 

Bone Marrow Recovery 

Bone marrow can be collected and cryopreserved. Conditions that can be treated by transplantation include bone marrow diseases, histiocytic disorders, hemoglobin opathies, inherited immune system disorders, inherited metabolic disorders, leukemias and lymphomas, myelodysplastic syndromes, multiple myeloma, plasma cell disorders, other cancers and malignant diseases. The inclusion of AAGP will increase functionality and viability of the bone marrow. This could then be expanded to all cryopreserved cells. 

Cord Blood Preservation 

Cord blood is the blood left in the umbilical cord and placenta immediately after birth. It can be collected, stored and used at any time during a baby’s lifetime to treat a wide variety of diseases and medical conditions. Cord blood is currently being used to treat multiple forms of cancer, hematopoietic diseases, inborn errors of metabolism and immune system diseases. You guessed it, AAGP will improve viability and function of the stored cord blood cells. 

Ischemic Stroke Repair 

Ischemic Stroke is associated with severe disabilities and a high recurrence rate. Testing of AAGP™ molecule is to prove it suppresses the inflammatory attack caused by ischemic stroke thereby preventing any long-term damage to the human body. 

I could continue but I think that I’ve made my point. AAGP part of the future for the treatment of cancer, blindness, diabetes, transplants, stroke… AAGP conceivably could be used in every cutting edge treatment that we are currently aware of. We’re not just talking about one of two things it can treat, as stated before we are truly talking about nearly every ailment that affects the human body. 

To be clear, these things are currently in trials and studies, but the results have been nothing but positive. Last year they announced their first working relationship with a large unnamed international biotech company. I believe we will see more of this. Given the enormity of the possibilities of this molecule, I see only one outcome for ProtoKinetix and that is a sell of the company. They are just too small to capitalize on such a vast technology. 

Now that I’ve covered the science and its potential, let’s get into the nuts and bolts of the company. The company was essentially left for dead in 2012. No filings were made for over 18 months and the demise of the company was a given. Then in 2014, through the efforts of the current CEO, the company was revived. This is not the typically outcome for a micro-cap that is in trouble. By mid-2014, the company was current of their filings and back up and running. They also moved from Canada to the US. 

Not only did they get going again, they are one of the tightest ran micro caps you will find. The 2018 cash burn for the company was just under $600k. This is remarkable for any public company but even more so for a biotech. In part they are able to keep expenses low due to the fact that most of their trials and studies are Investigator Sponsored by the University of Alberta, so the company isn't the one footing the bill for the research. Another reason for the low expense is the CEO’s salary is $1 a year. More on him later. To top it all off the company not only has no convertible debt it has no debt at all. Unheard of for a small biotech. 

One last compelling thing about this company is the amount of insider buying. I can safely say; I have never seen as many Form 4’s from a company as I have seen from PKTX. The buying has been significant. To give you an idea, the current CEO’s initial form 3 that was filed in June of 2014, showed him owning 19,670,500 shares. His most recent form 4 shows him owning 61,353,833 shares. I’ll save you the math exercise, that is an increase of over 41 million shares. Some have been acquired through private placements, but a huge number have been bought in the open market. The past and current CFO were and are regular Form 4 filers as well. 

So, the big question? Why is PKTX only trading at .08 with a $22 million market cap. There are a few reasons. 

Like CSBR, they have been spending their time on building a business and increasing the value of their technology, rather than spending their time on pumping their stock up. 
History. Like I said, the stock was left for dead and forgotten about. It takes a long time to recover from that. And legacy shareholders, I’m sure took advantage of an opportunity to get out, once they had the chance. 
It’s a tough environment for OTC stocks. In a market that has been as good as what we’ve seen the last few years, people are content with the easy money being made in the big names. 
Why buy now? 

The technology…AAGP is a life changing molecule. Nearly unlimited upside. 
Last year’s announcement of a Material Transfer Agreement with a global biotech company. Although the market didn’t take much notice, this is significant. It’s official, the big boys are starting to explore the AAGP molecule. 
Data/Trials/Studies – Press this week announced they expect results from Phase 3 testing for Retinal Cell Replacement. Data is king and we’re starting to get it. Data is what will bring big biotech knocking…along with their checkbook. 
No debt 
Insider buying 
It’s cheap. $22 million market cap is nothing for a company with a technology of this potential. 
I do believe the time is now. ProtoKinetix not only has a life changing molecule, I’m also betting that PTKX will be a life changing stock. 

Disclosure: I am/we are long PKTX, CSBR. 

 

      

 

PROTOKINETIX INC.
CORPORATE OFFICE
412 Mulberry St, 
Marietta Ohio 45750, USA 
Tel: (304) 299-5070 
EMAIL: contact@protokinetix.com

CEO:
Clarence E. Smith

BUSINESS MODEL

ProtoKinetix is building value for investors through licensing and joint ventures with business partners, utilizing our internationally patented technology- which is comprised of a family of glycoprotein compounds - targeting biotechnology applications where existing and developing businesses have requirements that AAGPs™ - anti-aging glycopeptides - will dramatically improve.

The biotechnology business is often subject to expensive and time consuming regulatory processes. Our approach is to expedite the development of our technology primarily through business relationships that provide us with leading-edge technical and marketing expertise to expedite the time lines to place products on the shelf.

ProtoKinetix is not about building a business with "bricks and mortar." We believe there are so many AAGP™ applications that can best be reached through strategic business relationships.

We assess each opportunity with return on investment as the priority. Defining and measuring each agreement based upon corporate investment, time line to market, strength of the organization within a specific market segment and marketing strengths.

As we build the value of AAGP™ we are also taking steps to generate revenue through sales of products in markets that do not require regulatory oversight.

COMMERCIAL APPLICATIONS

ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®

1. Ocular irritation studies
   Proof of concept pre-clinical DED trials for efficacy
   Confirmatory pre-clinical DED trials for efficacy
   Pilot drug stability (ie. shelf-life) testing
   Pilot tolerability and toxicology studies

1. Complete topical application formulation(s)
   Confirmatory DED efficacy tests
   Drug product Good Lab Practice (GLP) IND-enabling safety toxicology
   Communicate with Fedral Drug Administration (FDA) on clinical trial design criteria

***PKTX...Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP(R) Enhanced Stem Cell Vision Restoration 

MARIETTA, Ohio--(BUSINESS WIRE)--April 07, 2021-- 

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced the publication of a peer reviewed research paper describing and interpreting the results examining the benefit provided by AAGP(R) to enable human induced pluripotent stem cell (iPSC) derived retinal precursor cells transplanted to restor vision in an experimental model of blindness due to retina degeneration. The paper has been published by the prestigious Journal of Tissue Engineering and Regenerative Medicine. The focus of this journal is therapeutic approaches which combine stem/progenitor cells with bioactive agents to restore, maintain, or improve tissue or organ function. 

Journal of Tissue Engineering and Regenerative Medicine Paper on ProtoKinetix AAGP(R) 

Vision loss due to degeneration of the retina, most commonly the macula, commonly appears with aging, comorbid cardiovascular conditions, genetics, or other exposures. Age-related Macular Degeneration (AMD) currently has no cure and is the leading cause of blindness in the USA after deterioration in loss of reduced sharp central vision necessary for daily tasks like reading or driving. By 2050, the number of people in the USA with AMD is estimated to be 5.44 million. Age-Related Macular Degeneration (AMD) Data and Statistics 

Cells transplanted without AAGP(R) offered no benefits in electroretinography (ERG) or optokinetic tracking (OKT), which are advanced techniques used to measure vision function. By comparison, AAGP(R) treated cells showed 3-fold greater improvement in both ERG & OKT -- with more transplanted cells surviving long-term in the retina. Only AAGP(R) treated cells showed maturation and integration with the host retina. This overcomes a significant challenge not previously achieved to offer new hope for AMD patients and opportunity for cell therapy products to succeed for clinicians in need of protecting cell for transplant. 

This study was completed by Dr. Kevin Gregory-Evans, MD, PhD, Professor of Opthalmology & the Julia Levy Leadership Chair in Macular Research at the University of British Columbia. A panel member of the California Institute of Regenerative Medicine & Canadian Institutes of Health Research. Previously, a reader in molecular ophthalmology at Imperial College London. An ophthalmologist and global leader in macular research and regenerative medicine development. 

"We have now completed both structural and functional studies in cell transplantation in model systems of blindness. Concurrent use of PKTX-001 has shown to significantly improve cell survival and integration into host tissue and will be a valuable asset in the field of regenerative medicine in the future". -- Dr. Kevin Gregory-Evans M.D., Ph.D. 

Dr. Kevin Gregory-Evans on ProtoKinetix AAGP(R) 

Dr. Gregory-Evans Bio 

"We are happy to celebrate this milestone, which is the product of 5-years of intense research. This enables us as a company to focus on development and we will be looking forward to disclosing more on that in the near future." -- Clarence Smith, CEO President 

Global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc. According to market research published by iHealthcareAnalyst, the global market for organ transplantation is estimated to reach $51 billion by 2025, growing at a CAGR of 9.9% over the forecast period, driven by an aging population with increasing incidence of chronic disease, organ failures, and rising demand for transplant products, such as tissue products, immunosuppressants, and organ preservation solutions. 

See the promising research of AAGP(R) and results to date 

Visit our new website at ProtoKinetix.com for more information and to join our email list. 


 Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision..
11/24/2020 

ProtoKinetix AAGP® Restores Vision in Blind Test Subject
                                                                                                September 15, 2020                                                                                                
 ***ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of extensive testing, evidence of fully functional retinal cells was conclusively achieved. Based on these results Dr. Kevin Gregory-Evans shortly submitting a paper for publication in a peer reviewed journal.

Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada 

Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada
                                                                               July 13, 2020                                                                                                           
 ....ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of March 24, 2020. The ammendments to the clinical trial protocol have been submitted by the University of Alberta to Health Canada for their review.  Upon approval from Health Canada and upon final approval by the University of Alberta ethics committee, the Company will be immediately delivering over 75-grams of the PKX-001 to the University to accommodate the ongoing clinical trial.

ProtoKinetix AAGP® Dry Eye Program Advancing
                                                                                                        July 7, 2020                                                                                                                  ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.  

• EyeCRO has been contracted to conduct confirmatory testing and dose ranging. Early progress reports from EyeCRO will be received over the next two weeks.
  Charles River have been contracted to conduct pilot toxicology studies, to start at the end of July 2020. Early stage indications are expected by mid-August 2020.
  Stability tests have been completed by Ambiopharm. The tests were conducted at room temperature, in a provisional formulation, under non-sterile conditions. These preliminary results are extremely encouraging.

           ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine
                                                                                                       
                                                                      February 19, 2020                                                                         

  ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders “Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage and improved viability when challenged with multiple stressors,” said esteemed biochemist and toxicologist, Dr. Thomas Pulinilkunnil. “This in vitro data supporting the therapeutic utility of PKX-001 is expected to augment the progress of the whole organ and animal studies while screening PKX-001 for inflammatory, hypertrophic and ischemic pathologies in cardiovascular medicine.”

ProtoKinetix AAGP(R) Dry Eye Therapy Program Launched 

11/22/19 

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces the initiation of a program testing AAGP(R), to develop a potential therapy to treat Dry Eye Disease (DED). AAGP(R) has repeatedly demonstrated anti-inflammatory and cytoprotective properties, and also exhibits pharmaceutical properties beneficial for topical formulations. 

The eye is extremely sensitive, so before efficacy testing can commence an eye irritation study will be conducted in accordance with both industry and regulatory requirements. This testing has been contracted to ITR Laboratories of Montreal who are a well-recognised CRO in this area. This testing is scheduled to commence in early December with results before January 2020. 

About ITR Laboratories 

In anticipation of a successful result from ITR Laboratories, EyeCRO, from Oklahoma City, have been contracted to conduct the efficacy testing. This testing will involve topical application of AAGP(R) and evaluations of its effects on ocular inflammation. EyeCRO are world recognised, specialised CRO in the field of pre-clinical ocular drug research and development. This program will commence in early January 2020 and is expected to run for 3-4 months. 

About EyeCRO 

About Dry Eye Disease 

Dry Eye Disease is a condition in which a person does not have enough quality tears to lubricate and nourish the eye. Tears are necessary for maintaining the health of the front surface of the eye and for providing clear vision. Dry Eye Disease is a common and often chronic problem, particularly in older adults. This condition currently afflicts more that 30-million Americans (430-million people globally) and can affect as much as 40% of the population for various reasons. The dry eye disease ophthalmic market is very active, with $7.7 billion in revenues and a current growth of 12.5% CAGR. 


Tests Show AAGP® Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestone

Agreement Secured by ProtoKinetix to Start Heart Research Product Validation Studies 
May, 09 2019

MARIETTA, Ohio--(BUSINESS WIRE)-- ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is announcing that the Company has secured a partnership agreement with IMPART investigator team Canada at Dalhousie University and has now commenced studies to reveal the benefits of PKX-001 (AAGP®) in cardiac metabolism. These studies will determine the efficacy of PKX-001 as a cardioprotectant and will be led by Diabetes Canada Scholar, Dr. Thomas Pulinilkunnil. As the director of the IMPART cardiometabolic research program, Dr. Pulinilkunnil leverages extensive training in molecular and metabolic sciences from his training at the University of British Columbia, the University of Alberta Heart Institute and Harvard Medical School. Dr. Pulinikunnil is currently a tenured Associate Professor at Dalhousie University, Faculty of Medicine in the Department of Biochemistry and Molecular Biology. Dr. Pulinilkunnil will utilize sophisticated techniques and experimental models of type-2 diabetes, cardiac ischemia, and cardioncology to evaluate the therapeutic utility of PKX-001 as a cardioprotectant. 

Cardioprotectants are used extensively in hospital settings when the circulation is bypassed. They are components of cardioplegia solutions that protect the heart of patients from ischemia (low blood flow), such as during open-heart surgery or in preparation for heart transplantation. The metabolic protection identified in work-to-date by research laboratories using the ProtoKinetix product, AAGP®, as part of the Company’s product development strategy, has also opened up the potential for therapeutic protection of the heart during chemotherapy. Cardioncology is an emerging field of interest globally, as the cure rates of chemotherapy continue to improve and extend life. Ensuring that the heart is safe during chemotherapy is of paramount importance to several treatments regimens. 

“I am very optimistic that our program will determine the therapeutic utility of PKX-001 as a cardioprotective molecule and I am confident that our team will identify, at least in part, some of the molecular mechanisms involved in the functionality of PKX-001. Glycopeptides, such as these, are inherently fascinating to me because they were inspired by the natural world. As such, the fundamentals have already been established biologically in nature in demonstrating their ability to self-protect tissues from harmful conditions like cold temperatures, low oxygen, and exposure to toxic agents. Developing innovative therapies inspired by fundamental science is exciting to me and our research team.” – Dr. Thomas Pulinilkunnil 

About IMPART investigator team Canada 

IMPART is a growing consortium of scientists and clinicians that are collaborating to better understand the common threads of chronic disease related molecular pathophysiology. The team seeks to deliver innovative medical solutions through research, development, and clinical trials. The focus of this consortium is to address the unmet medical needs of special populations and medical conditions involving inflammation, metabolism, and physical abilities through research translation. The team is particularly concerned with vulnerable patients, as they have the most to gain from new medical innovations. The team uses an interdisciplinary approach to develop research questions, as well as uncover and deploy novel solutions for unmet medical needs.


ProtoKinetix AAGP® in Phase 3 Retinal Replacement Program

***PKTX...ProtoKinetix Releases Second in a Series of Scientific Update Videos 

January 16, 2019

MARIETTA, Ohio--(BUSINESS WIRE)--ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the launch of the second in a series of informational videos by the Principal Investigators in each field currently being tested. 

The second video is an update on the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells over a four-week period, we are now expanding the study. The new study shall include two animal models over a longer period of time to test whether the AAGP® treated cells continue to develop into retinal cells to potentially restore vision in humans. The study is being conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia. 

Dr. Kevin Gregory-Evans on AAGP™http://protokinetix.com/videos/ 


ProtoKinetix Releases First in a Series of Scientific Update Videos 

December 19, 2018 

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces the launch of the first in a series of informational videos by the Principal Investigators in each field currently being tested. 

The first video is an update on the clinical trial of AAGP™ PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type 1 diabetes led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta. 

Dr. James Shapiro on AAGP™ 

Click here for more on Dr. Shapiro and the Edmonton Protoco
****Here's a link.. http://protokinetix.com/videos/ 

  ProtoKinetix AAGP® Molecule Moving Forward in Key Healthcare Studies Targeting Important Health Care Solutions
 September 4, 2018

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) 

ProtoKinetix Enters into 3rd Phase of Retinal Cell Replacement Therapy Testing at UBCPress Release..
 08/10/2018 

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells over a four-week period, we are now expanding the study. The new study shall include two animal models over a longer period of time to test whether the AAGP® treated cells continue to develop into retinal cells to potentially restore vision in humans. The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia. 

Dr. Gregory-Evans Bio 

The studies to date demonstrated that in vitro pre-treatment of PPCs with 4 mg/mL PKX-001 resulted in a substantial increase of cell survival following their transplantation into the subretinal area of immunocompromised rabbits with retinal degeneration. PPCs treated with PKX-001 maintained their ability to express key proteins associated with photoreceptor functions. 

Based on the outstanding results thus far, ProtoKinetix now has patents pending in the United States of America, Canada and Europe. 

ProtoKinetix will now extend its previous studies into further in vivo functional studies. To date we have histological data ex vivo and in vivo that PKX-001 improves PPC survival and that these cells mature to express proteins of mature photoreceptors. 

The global ophthalmic therapeutics/drug market is expected to reach USD $35.7 billion by 2025, according to a new report by Grand View Research, Inc. 

ProtoKinetix Has Entered into a Research Agreement with The University of British Columbia to Test the Effect of its AAGP™ on Monoclonal Antibody Production and Bone Marrow Recovery 
 January 10, 2018 

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to announce that it has entered into a research agreement with The University of British Columbia (UBC), under the direction of principal investigator Dr. Kelly McNagny, Professor, Faculty of Medicine, Department of Medical Genetics. 

Dr. Kelly McNagny Bio 

This research agreement is to test and determine the effect of AAGP™ on monoclonal antibody production and bone marrow recovery. 

The University of British Columbia’s Antibody Lab will test whether AAGP™ enhances the production of monoclonal antibodies from cell lines, an important manufacturing issue for current immunotherapies. UBC will also test whether AAGP™ enhances the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy. 

The goal will be to determine whether AAGP™ enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation. “If AAGP™ could enhance survival or, better still, aid in the expansion of stem cells in vitro, this would be of enormous clinical benefit” – said Dr. Kelly McNagny, Professor of Medical Genetics, UBC. 

The goal of a bone marrow transplant is to cure many diseases and types of cancer. When the doses of chemotherapy or radiation needed to cure a cancer are so high that a person’s bone marrow stem cells will be permanently damaged or destroyed by the treatment, a bone marrow transplant may be needed. Bone marrow transplants may also be needed if the bone marrow has been destroyed by a disease. 

A bone marrow transplant can be used to: 
Replace diseased, non-functioning bone marrow with healthy functioning bone marrow (for conditions such as leukemia, aplastic anemia, and sickle cell anemia). 
Regenerate a new immune system that will fight existing or residual leukemia or other cancers not killed by the chemotherapy or radiation used in the transplant. 
Replace the bone marrow and restore its normal function after high doses of chemotherapy and/or radiation are given to treat a malignancy. This process is often called rescue (for diseases such as lymphoma and neuroblastoma). 
Replace bone marrow with genetically healthy functioning bone marrow to prevent further damage from a genetic disease process (such as Hurler's syndrome, adrenoleukodystrophy or severe combined immunodeficiency (SCID)). 

BIOGRAPHY - DR. KELLY MCNAGNY 

Dr. Kelly McNagny obtained his Ph.D. in Cellular Immunology at the U. of Alabama at Birmingham in 1990.  There he worked with Dr. Max D. Cooper (Howard Hughes Medical Institute, National Academy of Sciences) and his research focused on cell surface proteins that regulate B cell maturation and homing.  He then moved to the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany where he performed his postdoctoral studies in the lab of Dr. Thomas Graf from 1991 to 1996.  There his work focused on transcriptional control of hematopoietic stem cell maturation and cell fate. He performed some of the first studies to identify transcription factors that regulate the gene expression and differentiation of eosinophils, which are known to play a major role in allergic and asthmatic responses.  In addition, he identified a number of novel hematopoietic stem cell surface proteins (the CD34 family) and began analyzing their function.  He continued his studies at the EMBL as a semi-independent, Visiting Scientist from 1996 to 1998 prior to starting his own laboratory at The Biomedical Research Centre, at UBC. 

He is currently a full professor in Medical Genetics at The Biomedical Research Centre where his work focuses on stem cell behavior, inflammatory disease, cancer biology and therapeutics. 

In 2015 he also served as the Scientific Director of the Centre for Drug Research and Development (CDRD), a National Centre of Excellence aimed at translating early stage scientific discoveries into therapies.   

He has garnered several awards including the 2004 Showell-Pfizer Junior Faculty Award from the American Association for Immunology, a MSFHR Career Investigator Award and a visiting professorship at the Phillip's University of Marburg. Kelly is a member of the Canadian Stem Cell Network Centre of Excellence (Sub-Chair of the Trainee Education Committee), Associate Director of the AllerGen Network Centre of Excellence, and Co-Director of AllerGen'sBiomarkers and Bioinformatics Platform. 


***The Effects of ProtoKinetix’ Anti-Aging Glycopeptide (AAGP™) on Immune Cell Banking and Functions Relevant to
Immunotherapy 
November 16, 2017 

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to provide a scientific update on immune cell banking and functions relevant to immunotherapy using AAGP™ in collaboration with Proactive Immune Sciences. Earlier in 2017, Proactive initiated a research program which utilized an anti-aging glycopeptide (AAGP™) produced by ProtoKinetix Inc. which, amongst other uses, has shown the potential to benefit various cells during cryopreservation. In this research program, Proactive is investigating whether the AAGP™ produced by ProtoKinetix Inc. improves survival and function of cryopreserved immune cells by focusing on the following objective: 

1) Assessment of the effect of AAGP™ on cryopreserved immune cell viability and functionality. 

Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. Proactive Immune Sciences Corporation will collect and cryopreserve all of the different types of immune cells present in blood for its clients. These cells can be used later for any form of immunotherapy the client might require. These cells can also be used for immune system regeneration to help restore an immune system that is compromised from chemotherapy or radiation treatments or even old age. Although cryopreservation of cells is commonly performed, Proactive would like to offer its clients the most advanced methods to ensure their cells are in optimal conditions for the processing required for these immunotherapies. 

In May 2017, Proactive, with the support of the National Research Council of Canada (NRC) through an Industrial Research Assistance Program (IRAP) Grant, began testing AAGP™ in the cryopreservation process used to store Peripheral Blood Mononuclear Cells (PBMC). Cells were frozen using Proactive’s cryopreservation “cocktail” along with various concentrations of AAGP™. 

A combination of Proactive’s cryopreservation “cocktail” and AAGP™ resulted in a 45% increase in viability of PBMCs over that of Proactive’s cryopreservation “cocktail” alone. When T and B cells were isolated from the frozen PBMCs post-thaw, both cell types displayed greater viability as well. These positive results were repeated with JURKAT cells, a T cell line used for research. 

These findings have significance for immune cell based therapies. A 45% increase in the viability of PBMCs through the freezing process will result is significantly more cells being available should they be needed later for immune system reconstitution, requiring far less blood to be drawn. For patients, whose immune systems have been compromised from chemotherapy and/or radiation therapies, it could mean that they would now be able to participate in immune based therapies for which they previously could not provide enough viable cells. 

Improved viability of T and B cells in the presence of Proactive’s cryopreservation “cocktail” and AAGP™ may provide a better starting material for the processing involved in several cellular therapies in development or recent approval such as CAR-T therapy for cancer. 

The next phase of our research will explore the impact of Proactive’s cryopreservation “cocktail” and AAGP™ on functions of the immune cells pertinent to these developing cellular therapies. 

About Proactive Immune Sciences 

Proactive stores (banks) immune cells, while people are healthy, for them to use later in life should they contract cancer or have other immune system related diseases. 

Having the rights to AAGP™ for immune cell cryopreservation enables Proactive to establish a unique foothold in the cell banking market and to provide services to other organizations that use frozen immune cells in their therapeutic processes. 
 

Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery

                                                                                                       Oct 17, 2017

OTC Disclosure & News Service

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) is pleased to provide a scientific update to its stockholders. The Company is exploring the following areas for the use of its AAGP™ family of molecules:

Presently at the University of Alberta:

1. Diabetes (study started February 2017)

The PKX-001 (AAGP™’s clinical name) Study is treating islet cells prior to transplantation into human test subjects. The clinical trials are assessing any side effects or physiological damage to the test subjects. The study is looking for indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells.

The clinical trials are well underway and will continue throughout the end of the year with enrollment of up to ten patients. To obtain additional information and updates regarding the trials please use the following link: Clinicaltrials.gov - Islet Transplantation Using PKX-001.

2. Kidney Ischemia (anticipated start date 4^th quarter 2017)

Ischemia is a condition that occurs when blood flow to cells, tissues or organs is severely restricted. This condition can affect any part of the human body. When this circumstance transpires, cell death and organ damage follows very rapidly. Ischemia is a major cause of kidney damage, heart attacks and strokes.

Our testing is to determine whether AAGP™ can reduce the inflammatory response that causes cell damage and organ failure that occurs during an ischemic attack.

3. Normothermic Liver Perfusion (start date to be determined)

Normothermic (body temperature), ex vivo (outside the body) liver perfusion (method of irrigation) is an innovative therapy applied to donor livers outside of the body before transplantation that improves organ quality and makes organs that were previously unsuitable safe for transplant.

Our planned testing is to determine the beneficial effects of adding AAGP™ to the perfusate solution. Perfusate solutions are used to protect donor organs from the period of harvest until transplantation. We hope to evidence that AAGP™ can extend the viable life of harvested transplant organs.

Presently at the University of British Columbia:

1. Retinal Cell Replacement (started June 2016)

The research program at the University of British Columbia, under the guidance of Dr. Gregory-Evans will be determining whether AAGP™ can help improve the survival of stem cells that are currently being used in human trials to treat retinal blindness. We are doing this because of the poor outcome in the current state of play using stem cells in the treatment of blindness. Proof of principal work has been done in animal models but these successes are few and far between. What has been seen most recently is that probably as few as 10% of injected cells are surviving more than a week. Although this is adequate for proof of principle work, it is not good enough for developing a clinical medical treatment. We are looking for ways to improve cell survival in actual living eyes.

The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia compared the results of transplanted retinal precursor cells with and without the addition of AAGP™. The cells treated with AAGP™ showed a dramatic improvement on cell survivability and viability, functionality compared to the untreated cells. Ongoing testing is now being conducted to determine if these transplanted cells are fully functioning.

2. Monoclonal Antibody Production (anticipated start date 4^th quarter 2017)

Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope. The use of monoclonal antibodies to treat diseases is called immunotherapy because each type of monoclonal antibody will target a specific targeted antigen in the body. Monoclonal antibodies are currently being used to treat Cancer, Rheumatoid Arthritis, Multiple Sclerosis, Cardiovascular Disease, Systemic Lupus Erythematosus, Crohn's Disease, Ulcerative Colitis, Psoriasis, Transplant Rejection, and several more conditions.

By adding AAGP™ into the culture medium, we are hoping to show a substantial increase in viable monoclonal antibodies that could lead to a dramatic decrease in the cost of production of monoclonal antibody medicines.

We are working at initiating programs on:

1. Bone Marrow Recovery (preliminary stage)

Bone marrow is the flexible tissue in the interior of bones. In humans, red blood cells are produced by cores of bone marrow in the heads of long bones in a process known as hematopoiesis. It can be collected and cryopreserved. Conditions that can be treated by transplantation include bone marrow diseases, histiocytic disorders, hemoglobin opathies, inherited immune system disorders, inherited metabolic disorders, leukemias and lymphomas, myelodysplastic syndromes, multiple myeloma, plasma cell disorders, other cancers and malignant diseases.

We will be testing to prove the viability and functionality of cryopreserved bone marrow increases with the addition of AAGP™.

2. Cord Blood Preservation (preliminary stage)

Cord blood is the blood left in the umbilical cord and placenta immediately after a baby is born. It can be collected, stored and used at any time during a baby’s lifetime to treat a wide variety of diseases and medical conditions. Cord blood is currently being used to treat multiple forms of cancer, hematopoietic diseases, inborn errors of metabolism and immune system diseases.

We will be testing to prove the viability and functionality of cryopreserved cord blood cells increases with the addition of AAGP™.

3. Ischemic Stroke Repair (anticipated start 4^th quarter 2017)

Ischemic Stroke is usually associated with severe disabilities, high recurrence rate and other poor outcomes. Currently, there are no long-term effective treatments for stroke. Cell therapies have been explored previously. However, the therapeutic outcomes are often limited by poor survival of transplanted cells, difficult delivery, uncontrolled cell differentiation, ineffective engraftment with host tissues and non-sustained delivery of growth factors.

We will be testing to demonstrate that the AAGP™ molecule suppresses the inflammatory attack caused by ischemic stroke thereby preventing any long term damage to the human body.

Proactive Immune Sciences is conducting research on:

1. Immune Cell Cryopreservation Recovery (started June 2017 - anticipated end date 4^th quarter 2017)

Immune based interventions represent one of the fastest growing, most promising areas of personalized medicine. This is particularly true for cancer, which is largely a disease of immune failure. Therefore, there is a strong impetus for individuals to bank healthy immune cells at as early an age as possible, before these cells are compromised by infection, malignancy, or simply advanced immunological age. The ability to use immune cells provides an oncologist another major tool in their arsenal to fight cancer.

Results to date have been very encouraging. We are hoping to prove the functionality of cryopreserved immune cells increases with the addition of AAGP™ on the immune cell cryopreservation protocols used by Proactive Immune Sciences.

“We are delighted that research continues to support a growing belief in the potential benefits of AAGP™ for an expanding spectrum of medical applications. Through our international partnerships and academic relationships, we continue to explore and participate in well-designed scientific studies in support of a fundamental understanding of how AAGP™ can benefit numerous medical conditions. We are encouraged by the growing clinical data to support the effectiveness of AAGP™. I look forward to updating our stockholders with additional results as they become available as well as releases that will give a better understanding as to why we are conducting the study.” - Clarence E. Smith, President and Chief Executive Officer.
 

ProtoKinetix Announces Start of Phase 1 & Phase 2 Clinical Trials for the use of AAGP™ PKX-001 Treated Islet Cells in the Treatment of Type 1 Diabetes

ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration 

2017-02-07  

Company Website: http://www.protokinetix.com 
ST. MARYS, W. Va. -- (Business Wire) 

ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of British Columbia (“UBC”) under the guidance of Dr. Gregory-Evans. 

As explained by Dr. Gregory-Evans, the research program at UBC will be determining whether AAGP™ can help improve the survival of stem cells that are currently being used in human trials to treat retinal blindness. We are doing this because of the poor outcome in the current state of play using stem cells in the treatment of blindness. Proof of principal work has been done in animal models but these successes are few and far between. What has been seen most recently is that probably as few as 10% of injected cells are surviving more than a week. Although this is adequate for proof of principle work, it is not good enough for developing a clinical medical treatment. We are looking for ways to improve cell survival in actual living eyes. 

The researchers at UBC have reached the conclusion that AAGP™ should provide the required level of protection to ensure post-engraftment survival. One reason is theoretical and one is experimental. The theoretical basis is that when tissue is damaged, that tissue breaks down and releases toxins into its environment. We believe that AAGP™ can work to reduce the harmful effects of these toxins. Based on previous tests conducted by the Company, AAGP™ has demonstrated significant anti-inflammatory properties. The experimental basis for our hypothesis is that we have tested the drug in tissue culture in the lab and found that it improves the survival of cells. 

The current work that we are doing is taking those results and that theory and looking at it now in living tissue to see if we can reproduce the successes that we achieved before. We have established a new type of model for retinal degeneration in a rabbit and are currently working on injecting neuronal cells plus AAGP™ to see if we can see any improvement long term in how these cells survive and integrate into the retina and hopefully lead to vision restoration in the animals. 

“We hope to achieve results in experiments more closely aligned with human disease. If that is the case the molecule could become a major advance in the field of stem cells and blindness.” Dr. Kevin Gregory-Evans, Professor of Ophthalmology in the Faculty of Medicine, University of British Columbia 

 

Protokinetix AAGP™ research focuses on unique healthcare solutions that can provide cell survival which prolong the life of a cell, which is crucial in many medical research and procedures done today.

Acute medical research study is always progressing, but one of the problems that researchers rely on is the benefit from solutions that can deal with the fundamental factors of inflammation and oxidation. Both are well-known causes of life-threatening conditions and diseases, and accelerated aging. In addition many acute medical problems are benefiting from cell therapies and transplantation of cell, tissues and organs.

AAGP™ is now being used or investigated as a possible solution by many healthcare companies that specialize in medical cell therapies, organ transplant, trauma, blood product banking and anti-inflammation.

AAGP™ has taken Protokinetix's research team into preservation of stem cells and cell therapy, storage of blood platelets and blood products, harvesting and transplantation of islet cells for diabetes treatments, time sensitive organ transplantation and inflammation causing diseases and conditions.

Protokinetix expects to license several commercial applications from its AAGP™ family as well as expand its ongoing research and development with institutions and businesses. Protokinetix is actively in talks with several healthcare companies that are testing the molecule in their specific niche applications.

ProtoKinetix, Incorporated Announces Investigator Sponsored Clinical Trial Submitted to Health Canada for the use of AAGP(TM) in the Treatment of Type 1 Diabetes

ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announced that the Governors of the University of Alberta have submitted an Investigational Testing Authorization application to commence clinical studies in Canada. This authorization will allow the clinical trial group to enroll Canadian patients into the study.

"Based on extensive experiments in the lab we are clearly excited to take forward the AAGP(TM) molecule from the bench to testing in patients in partnership with ProtoKinetix. This anti-aging glycopeptide molecule has been exceedingly potent in protecting human islets from early damage after transplant from engraftment and anti-rejection drugs in our preliminary tests, and if these promising findings can be replicated in patients in the clinic receiving islet cell transplants today, and potentially stem cells in the future, this would represent a major advance." Dr. James Shapiro, M.D., Ph.D., FRCSC, Director of Clinical Islet Transplant Program, University of Alberta.

 Dr. James Shapiro 

"It is a remarkable achievement for a small biotech company like ProtoKinetix to be submitting a Clinical Trial Application (CTA) to Health Canada." Julia Levy, PhD, Chairman ProtoKinetix Business and Scientific Advisory Board.

 Dr. Julia Levy 

"I look forward to the opportunity to prove that AAGP(TM), used in the Edmonton Protocol, will greatly improve results in the treatment of Type 1 Diabetes in humans. I am very pleased that we have met the goals that we set out in January, 2016." Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.

About the PKX-001 Study

PKX-001 is the designation given to the drug product molecule of the AAGP(TM) family. Islet cell transplants are well recognized as a viable and effective treatment for T1 diabetes.

The PKX-001 Study will treat islet cells prior to transplantation into human test subjects. The clinical trials will be accessing any side effects or physiological damage to the test subjects. The study will also be looking for indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells.

ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP(TM)) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has submitted an Investigational Testing Authorization application to Health Canada to enter into a Phase 1/2 human clinical trial at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.

                                                                                                                              ProtoKinetix, Incorporated  Clarence E. Smith, 304-299-5070  President and Chief Executive Officer  csmith@protokinetix.com  Twitter: @ProtoKinetix

ProtoKinetix’ 2nd Quarter Scientific Update....

07/14/2016 

ST. MARYS, W. Va.--(BUSINESS WIRE)--Jul. 14, 2016-- (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:

The management team has been very busy since our last update. The following is a summary of our strategy and action in support of the Company’s direction.

Clinical Trial Application progress:

1. Method Development for toxicology studies that were conducted by ITR Laboratories Canada, Inc. (ITR).

2. Method Validation for toxicology studies to be conducted by ITR has commenced.

3. Molecular study for radiation stabilization has been completed by Iotron Industries Canada, Inc. (Iotron).

4. Bio Burden testing and Bio Burden Validation testing that was conducted by Nelson Laboratories, LLC (Nelson Labs) has been completed.

5. Certificate of Analysis for Drug Substance (GMP) for AAGP™ has been completed by Ambiopharm, Inc. (Ambiopharm).

6. AAGP™ has been shipped to Iotron to complete sterilization as required by the clinical trial protocols and returned to Ambiopharm.

7. A final report of pre-transplant AAGP™ treated islet cells analysis prepared by BRI Biopharmaceutical Research, Inc. (BRI).

8. We have completed the first draft of the Investigator’s Brochure (IB), a component of the clinical trial application to Health Canada. IB is a multidisciplinary document that summarizes the main elements of an entire development program to date. Although the IB also serves other purposes, it is written to enable investigators conducting clinical trial studies to assess the risks and benefits associated with an investigational product.

We are, at present, preparing a clinical trial application to Health Canada. This trial will be conducted by the Shapiro team at the University of Alberta on the well-established, Edmonton Protocol used for treatment of Type 1 Diabetes through islet cell transplants.

Neural Stem Cell Testing:

1. Testing on stem cells transplanted in retina tissue has been completed. This study was conducted at the University of British Columbia (UBC) and directed by Dr. Kevin Gregory-Evans. Stem cells tested with AAGP™ showed a 300% increase in engraftment survival over the control group.

2. The results of Dr. Gregory-Evans’ work were published in the Journal of Tissue Engineering and Regenerative Medicine, June 2016.

3. We have commenced a major study at UBC under the direction of Dr. Gregory-Evans for the effect of AAGP™ in the transplantation of human embryonic stem cells derived from neuronal type cells. This research holds significant potential for the treatment of conditions where neuronal cell death or damage has occurred. This includes age-related macular degeneration (AMD), stroke and spinal cord injury.

“I am extremely proud of how much we have accomplished in these last six months. I look forward to the future for this company that holds so much potential. I am grateful to all of those who have been involved in our progress.”-Mr. Clarence Smith.

We are looking forward to moving ahead with our application for clinical trials this year. We anticipate testing on the effects of AAGP™ on the preservation of whole donor organs and tissues for transplantation. We remain very confident in our strategy and appreciate your support of our actions to develop life-saving treatments for disease worldwide and to maximize financial returns to you, our stockholders and friends.

ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing the company is now preparing a submission to enter into a Phase 1/2 human clinical trial at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.

ProtoKinetix’ AAGP™ has been Published in the Journal of Tissue Engineering and Regenerative Medicine

                                                                                         06/07/2016 - Business Wire

AAGP™ Improves Results in Stem Cells Transplanted in Retina Tissue by 300%

                                                                                                 05/02/2016 - Business Wire

ProtoKinetix Outlines Steps to Clinical Trial Application for AAGP™

 04/26/2016 

ST. MARYS, W.Va.--(BUSINESS WIRE)--Apr. 26, 2016-- ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) outlines the steps to be completed for the application to conduct a clinical trial in Canada.

For the last four years ProtoKinetix has been involved in a collaboration with the Laboratory of Dr. James Shapiro, M.D., Ph.D., FRCSC, the director of the Clinical Islet Transplant Program at the University of Alberta Hospital. The outcome of these extensive tests resulted in a publication this February in the prestigious American Diabetes Association Journal, Diabetes and a planned submission to Health Canada of a clinical trial application (CTA). The CTA, for a Phase 1/2 study in patients, will involve the addition of AAGP™ to the well-established Edmonton Protocol for islet cell transplants for the treatment of type 1 diabetes.

Before a CTA can be submitted several rigorous tests and events have to be completed.

1. The molecule being tested has to be produced under current Good Manufacturing Practice (GMP) guidelines. GMP is an exacting standard of production that requires a validated and documented approach for each step of the process and a complete provenance for every component.

2. A Pharmacokinetic (PK) analysis with a validated methodology has to be completed on the molecule to determine AAGP™’s absorption and distribution throughout the human body.

3. The molecule has to be tested for toxicology, including evaluation of the genotoxic potential.

4. The end product must be certified as sterile.

5. An Investigator's Brochure has to be prepared incorporating these results as well as the Chemistry, Manufacturing, & Control (CMC) documentation provided by the GMP facility.

The CTA submission will be an Investigator-sponsored application from Dr. James Shapiro’s Laboratory.

In order to assist the Company in achieving a cost effective and timely CTA submission, ProtoKinetix has retained the services of the following experts and Contract Research Organizations (CROs):

Evelina Rubinchik PhD

Dr. Rubinchik is our contracted toxicologist who is organizing theselection of nonclinical CROs and management of toxicological studies. Dr. Rubinchik is also involved in the preparation of project budgets and timelines, review, and interpretation of toxicological data.

Dana Nohynek MSc, RAC

Ms. Nohynek is an independent regulatory consultant with expertise in Clinical Trial Application submissions and liaising with the Canadian regulatory authority.

PK Analysis CRO

BRI Biopharmaceutical Research Inc. is a specialized analytical, LC/MS/MS bioanalytical and DM/PK contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting IND and Toxicology CROs.

Toxicology CRO

ITR Canada Inc. is an international contract research organization that provides non-clinical toxicology services for the biotechnology and pharmaceutical industries with clients located around the globe. Operating in Montréal since 1989, ITR’s purpose-built preclinical research facility was designed to be optimized for quality technical and scientific research. A privately-held organization with more than 300 employees in Canada, ITR offers personalized services from planning and study program design to study implementation and reporting for regulatory drug filing. ITR Canada is CCAC and AAALAC accredited, and studies conducted are fully compliant with GLP.

Manufacturing CRO

AmbioPharm, Inc. (APi) is a full-service peptide manufacturing company headquartered in North Augusta, SC, USA. In its cGMP manufacturing facilities in the USA and Shanghai, China, it develops highly efficient processes for manufacturing peptides at small to very large scale as Active Pharmaceutical Ingredients used in New Chemical Entities and generic peptides by clients worldwide. 

 

ProtoKinetix Corporate Update..
Jan. 5, 2016

ST. MARYS, W. Va.--(BUSINESS WIRE)--Jan. 5, 2016-- ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:

AAGP Found to Significantly Improve Islet Cell Transplantation in Type 1 Diabetes Patients

Dec 17, 2015

ST. MARYS, W. Va. -- (Business Wire) --

ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that their molecule, AAGP, an antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of Cell Transplant Treatments for diabetes - a procedure that transplants insulin producing islet to render them insulin independent for periods of time.

Anti-Aging GlycoPeptide (AAGP), is the focus of a new study published in the journal Diabetes. Researchers from the University of Alberta's Faculty of Medicine & Dentistry found that by soaking islet cells in AAGP for an hour and then washing it off prior to transplantation, the cells were protected from tacrolimus an antirejection drug commonly used during transplants that is toxic to islets cells.  

Normally when we expose human islets to tacrolimus in the petri dish, they flat line and don?t release insulin at all, says James Shapiro, senior author of the study and Canada Research Chair in Transplant Surgery and Regenerative Medicine at the U of A. When we add the AAGP and wash it all off, the cells work perfectly normally, and are protected in a remarkably durable manner. We find we need far fewer cells to treat diabetes in our preclinical models than we would normally. 

Since his creation of the Edmonton Protocol in 1999, more than 250 patients have been treated by Shapiro through islet cell transplantation. A key challenge of the procedure though is that most patients typically need two islet infusions, each prepared from a separate pancreas organ donor. Shapiro says there aren't enough organ donors to meet demand. Through the use AAGP, a greater number of islet cells will survive the procedure, potentially allowing more patients to be treated.  

Just a one hour soak in AAGP is enough to protect the islet cells for up to a month or two afterwards. It has a very potent and profound effect, says Shapiro. As a direct result of these findings, we're now moving forward with plans for a first in human clinical trial?led at the University of Alberta?testing this drug in our human islet cell transplant program.? 

This synthetic molecule seems to provide significant protection to cells exposed to multiple deleterious conditions, such as UV radiation, starvation, extreme temperatures andoxidative stress, says Boris Gala-Lopez, lead author of the study and a clinical/research fellow at the U of A's Department of Surgery. We are certainly very excited for the multiple opportunities this finding entails to the field of transplantation research. 

Funding for the study was provided by the Diabetes Research Institute Foundation of Canada, while the drug AAGP was provided by ProtoKinetix.  

We are very excited to have our AAGP molecule showcased in this prestigious journal. We are also extremely confident in the ongoing success of our collaboration with Dr. James Shapiro and his outstanding team said Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.

If proven successful in human clinical trials, Shapiro believes the inclusion of AAGP could soon become a permanent addition to the Edmonton Protocol representing a significant step forward in the treatment of Type 1 diabetes through islet transplantation. While more research is needed, he also believes the drug shows promise for a wide range of transplantations?potentially working to protect organs as effectively as it protects islets. 

ProtoKinetix’ AAGP™ to Be Presented at the Congress of the International Pancreas and Islet Transplant Associatio
                                                                                                          09/10/2015 

ProtoKinetix Begins Testing Diabetic Mice with AAGP™ at the University of Alberta..

 09/18/2015

ST. MARYS, W. Va.--(BUSINESS WIRE)--Sep. 18, 2015-- ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that it has begun testing NOD (Non Obese Diabetic) mice with its AAGP™ molecule at the James Shapiro laboratory at the University of Alberta.

Type 1, diabetic NOD mice with AAGP™ versus a control group of Type 1, diabetic NOD mice without AAGP™ will be monitored for their blood-glucose levels. Using the NOD mice as a model the Edmonton team will be specifically assessing the potentially protective effect of AAGP™ against the antibody attack conducted against the islet cells in the pancreas.

NOD Mice, like the Bio-Breeding rat, are used as an animal model for Type 1 diabetes. Non-obese diabetic (NOD) mice exhibit a susceptibility to spontaneous development of autoimmune insulin dependent diabetes mellitus (IDDM).The NOD strain and related strains were developed at Shionogi Research Laboratories in Aburahi, Japan by Makino and colleagues and first reported in 1980.The group developed the NOD strain by an outbreeding of the cataract-prone strain from JcI:ICR mice.

At the conclusion of these tests, the internal organs of the NOD mice will be examined for any evidence of toxicity and bioavailability. This data is an extremely valuable step on the critical path towards submissions to Health Canada or the FDA for human clinical trial applications.

About the James Shapiro Laboratory

The James Shapiro Laboratory is active experimental laboratory working on improving long term survival of transplanted islets, and in immunomodulation of transplanted tissues. He is Principal Investigator on several NIH and JDRF-funded clinical trials, including clinical testing of costimulation blockade in islet transplantation.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release may contain statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.



View source version on businesswire.com: http://www.businesswire.com/news/home/20150918005068/en/

Source: ProtoKinetix, Inc.

ProtoKinetix, Inc.Clarence E. Smith, President & Chief Executive Officer304-299-5070csmith@protokinetix.com

***PKTX...ProtoKinetix Reports on Its Strong Collaboration with the James Shapiro Laboratory at the University of Alberta
                                                            August 4, 2015

***ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to report on its collaboration with the James Shapiro laboratory at the University of Alberta. The sole intention of the collaboration is to develop a commercial product pipeline of therapeutic applications for the AAGP™ family of molecules.

...Professor James Shapiro is Professor of Surgery, Medicine and Surgical Oncology, and Director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Program at the University of Alberta in Edmonton, Canada. He has a busy hepatobiliary surgical practice in HPB oncology, and in liver and kidney-pancreas transplant surgery. His center carries out 80 liver transplants per year, and has done around 80 living donor liver transplants. The University of Alberta just celebrated their 1000th liver transplant.

...Dr. Shapiro directs the largest clinical islet transplant program worldwide with almost 170 patients treated, and led the clinical team that developed the "Edmonton Protocol" - the first trial to achieve consistent 100% insulin independence in a series of islet-alone transplant recipients with Type 1 diabetes (published in the NEJM 2000). Before Dr. Shapiro’s trial, the success rate with islet transplantation was less than 8%. He led an international multicenter trial to replicate these findings in 9 international centers (published in NEJM 2006).

...Over the last 32 months Dr. Shapiro and his team have been extensively testing the AAGP™ molecule in allogeneic transplants using human islet cells as the model. As regenerative medicine is rapidly becoming adopted in the treatment of degenerative diseases, the protection of the transplanted cells, tissues, and organs is of paramount importance. Transplanted cells and tissues are subjected to extreme stress factors that, unless protected, could cause failure to graft or premature death. The success of the tests conducted in Edmonton have demonstrated that AAGP™ has the potential to be widely adopted in many areas of regenerative medicine.

.."I'm very excited about our ongoing collaborations with PKTX and by the remarkable potency of AAGP. This molecule has great potential, and we are just beginning to scratch beneath the surface," said Dr. James Shapiro.

...As a result of the tests, Dr. Shapiro and his team are developing further testing based on three primary activities:

..1. The ongoing testing and refinement of cellular transplantation using human islet cells as the demonstrated model. In particular, AAGP™ may provide powerful protection against hostile agents that severely inhibit engraftment success. Cell therapies are currently being developed around the world for the treatment of spinal cord injury, damaged heart tissue, stroke, diabetes as well as many other conditions.

..2. Human organ preservation. The program will assess the effect of AAGP™ in extending the transplant viability of donor organs. The Canadian National Transplant Research Program is a major national initiative involving the Federal institutes of health, all Provinces and the private sector. http://www.cntrp.ca/. The first testing will be conducted on livers to determine whether AAGP™ can extend the ex-vivo functionality of the organ.

..3. Auto immune disease. This class of diseases occur where the body's immune system starts to attack healthy cells. Diseases in this category include, rheumatoid arthritis, multiple sclerosis and Type 1 diabetes. Using the NOD (Non Obese Diabetic) mice as a model the Edmonton team will be specifically assessing the potentially protective effect of AAGP™ against the antibody attack conducted against the islet cells in the pancreas.

...“This impressive team of transplant surgeons and scientists have made clear to us the dramatic scope of applications that our family of molecules possesses,” said Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.

.....About the James Shapiro Laboratory

The James Shapiro Laboratory is active experimental laboratory working on improving long term survival of transplanted islets, and in immunomodulation of transplanted tissues. He is Principal Investigator on several NIH and JDRF-funded clinical trials, including clinical testing of costimulation blockade in islet transplantation.

                            **PKTX.. ProtoKinetix Upgrades to OTCQB... OFF of Pinks..!   
                                                            June 8, 2015

...ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that ProtoKinetix began trading today on the OTCQB(R) Venture Marketplace under the symbol "PKTX." The Company was formerly trading on the OTC Pink(R) marketplace under the same symbol.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company at: http://www.otcmarkets.com/stock/PKTX/quote.

"After considerable effort and significant investment in our public disclosure, we are proud to be trading on the OTCQB marketplace. This upgrade should broaden our shareholder base, improve liquidity and increase the visibility for our achievements going forward," said Clarence E. Smith, President and Chief Executive Officer of ProtoKinetix.

The OTCQB Venture Marketplace offers transparent trading in entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their financial reporting and must undergo an annual verification and management certification process. Companies must also meet a minimum one penny bid test and may not be in bankruptcy.

About ProtoKinetix

ProtoKinetix, Inc. (OTCQB: PKTX) is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP(TM)) that enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP(TM) molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

Clarence E. Smith -- President and CEO

**PKTX..CEO Clarence Smith Reports on Edmonton Meetings with Dr. James Shapiro and his Team...

 06/05/2015 

ST. MARYS, W.Va.--(BUSINESS WIRE)--Jun. 5, 2015-- ProtoKinetix, Incorporated(OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that CEO Clarence Smith recently returned from visiting Dr. James Shapiro at the University of Alberta. Mr. Smith met with Dr. Shapiro and his impressive team, including Dr. Boris Gala-Lopez. As previously announced, the Company has been heavily involved with the James Shapiro Laboratory for the last 24-months. Dr. Shapiro’s team has conducted extensive tests on islet cell transplantation using the AAGP™ molecule for the treatment of diabetes using AAGP™. Mr. Smith was impressed with the program and gratified that AAGP™ was proving to be a central element in the research.

Dr. Shapiro is a professor of surgery, medicine and surgical oncology. He is director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Programs at the University of Alberta. He is also principal investigator of National Institute of Health and the Juvenile Diabetes Research Foundation clinical trials. In addition to these positions, he is the leader of the Project 1 - Ex-vivo Organ Transplant Protection and Repair Program of the Canadian National Transplant Research Program.

Due to the excellent results of these tests on islet cell transplantation with AAGP™, Dr. Shapiro and his team are expanding their field of investigation to include:

1) Whole Organ Preservation

a. A major initiative of the Canadian National Transplant Research Program (CNTRP).

b. Preservation of hearts, lungs, kidneys, livers and transplantable tissue has become of critical importance to transplantation medicine.

2) Non Obese Diabetes (NOD) Mice

a. NOD mice are used as an animal model for Type 1 Diabetes testing.

b. Dr. Shapiro’s team shall be exploring the potential of AAGP™ to delay the progression of this disease.

“This impressive team of transplant surgeons and scientists have made clear to me the dramatic scope of applications that our family of molecules possess,” said Clarence E. Smith, President and Chief Executive Officer.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150605005032/en/

Source: ProtoKinetix, Inc.

ProtoKinetix, Inc.Clarence E. Smith, 304-299-5070President and CEO

***University of Alberta...Acquisition of Patent....

***ProtoKinetix Announces Acquisition of Patents.. 
 04/14/2015 

 ***ProtoKinetix Announces Acquisition of Patents

***University of Alberta Diabetes Institute Encouraged by Preliminary Results of Testing of ProtoKinetix Licensed AAGP™ Molecule in Islet Cell Transplantation

Mar. 26, 2015

...ProtoKinetix (OTC: PKTX) (www.protokinetix.com) is pleased to be able to report a comprehensive transplantation testing program being conducted for the last two years in conjunction with the University of Alberta transplant research team. The Company is collaborating with the James Shapiro Laboratory at the University of Alberta in Edmonton, Alberta. Dr. Shapiro directs the largest clinical islet transplantation program in the world.

Dr. Shapiro is a professor of surgery, medicine and surgical oncology. He is director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Programs at the University of Alberta. He is also principal investigator of National Institute of Health and the Juvenile Diabetes Research Foundation clinical trials. In addition to these positions, he is the leader of the Project 1 - Ex-vivo Organ Transplant Protection and Repair Program of the Canadian National Transplant Research Program.

During the last 24-months, Dr. Shapiro’s Ph.D. student, Dr Boris Gala-Lopez, and his team have conducted extensive testing with our AAGP™ molecule using human islet cells in transplantation, investigating its effect on engraftment, insulin production, protective effect against anti-rejection drugs and investigation of the mechanism of action. The results provided consistent encouragement to continue testing to develop protocols that can be applied to transplantation medicine.

Allogeneic transplantation is the transplanting of cells, tissues or organs from the same species, but not with the host DNA. Serious issues that have to be addressed are the engraftment of the transplanted organ or cells and the subsequent protection against the immune response. The protection, in the form of anti-rejection drugs, is toxic and causes damage to the graft. AAGP™ has been shown in these trials to increase engraftment and reduce the toxicity damage.

Dr. Shapiro says “We are all very encouraged by the early results of these studies, and I look forward to working with the Company in moving toward use of AAGP™ in future clinical applications”.

 

                                                                                                              

              ****Dr. Julia Levy Accepts Position on ProtoKinetix’ Business and Scientific Advisory Board 

....Discoveries made by her and colleagues at the University of British Columbia in the field of photodynamic therapy were the basis of the first medical treatment of macular degeneration, a leading cause of blindness among the elderly, a treatment was developed by QLT, Inc. She served first as Chief Scientific Officer and later as Chief Executive Officer of QLT. Dr. Levy is an officer of the Order of Canada and has received a number of honorary degrees. She has served on the boards of a number of companies as well as of charitable organizations. 

As ProtoKinetix continues to grow and to make the important transition to becoming a full-fledged clinical stage company, Dr. Levy’s in-depth experience and understanding of both the regulatory and business aspects of the biopharmaceutical industry are particularly valuable for the expansion and commercialization of AAGP™ applications. 

About Dr. Levy 

As co-inventor of Visudyne and co-founder of QLT, Dr. Levy served in several key senior positions at the company including Chief Scientific Officer as well as President and CEO. Under Dr. Levy’s leadership, QLT recorded the strongest period of growth in the company’s history and earned a reputation for achieving milestones, including FDA approval for Visudyne to treat age-related macular degeneration, the commonest cause of severe vision loss in the elderly. Dr. Levy has earned numerous awards and honours including an appointment as an Officer of the Order of Canada, the Female Entrepreneur of the Year for International Business, Pacific Canada Entrepreneur of the Year and the Future of Vision Award from the Foundation Fighting Blindness. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. In her honour, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the BC Biotechnology Association. In 2009, the province of British Columbia permanently endowed the Julia Levy B.C. Leadership Chair in Macular Research at the University of British Columbia (U.B.C.) in partnership with U.B.C. and QLT. 

About ProtoKinetix 

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™). These molecules have been demonstrated to protect cells against hostile conditions that are present in all areas of transplantation including regenerative medicine. 

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that areforward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission. 

Clarence E. Smith –President and CEO 
Source: ProtoKinetix 

ProtoKinetix, Inc.Blair Henderson604-926-6627 

***PKTX.. PROTOKINETIX, INCORPORATED. 
9176 South Pleasants Highway 
St. Marys, WV 26170 
 

                             ***ProtoKinetix Announces New President and Chief ExecutiveOfficer 
                                                               February 23, 2015 

...ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) (the "Company" or "ProtoKinetix") announces that a cease trade order issued by the British Columbia Securities Commission was revoked effective as of the date of this news release. 

..In connection with the revocation, the Company also announces that it has received and accepted the resignation of Mr. Ross Senior as a Director, President and Chief Executive Officer of the Company effective as of February 19, 2015. Mr. Clarence E. Smith has been appointed as the Company's new President and Chief Executive Officer. 

..ProtoKinetix further announces that it has moved its headoffice to 9176 South Pleasants Highway, St. Marys, West Virginia, USA 26170. 

About ProtoKinetix 

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, theCompany is currently targeting the direct treatment of diseases that have a major inflammatory component. 
ON BEHALF OF THE BOARD OF DIRECTORS 
PROTOKINETIX, INCORPORATED 
Clarence E. Smith 
President and Chief Executive Officer 
For further information, please contact: 
Clarence E. Smith, President & Chief Executive Officer 
Telephone: 304-299-5070 
Email: csmith@protokinetix.com 


                             ***ProtoKinetix’ Summary of Their Glyco Peptide (AAGP™) Molecule Development  
                                                                     06/17/14

...Over 10-years ago, ProtoKinetix (PKTX) commissioned INSA (French National Institute of Applied Science) to produce a small, stable, synthetic glyco peptide using their gem diflouride platform. The molecule selected was a mimic of a well characterized, glyco protein known as Anti-Freeze Glyco Protein (AFGP). The lead scientist from INSA was Dr. Geraldine Deliencourt. 

..During this period of time ProtoKinetix was working of the molecule, a new medical initiative arose from theory to maturity through extensive research conducted on stem cells. This field of research is collectively known as “regenerative medicine”. Regenerative medicine attempts to replace damaged cells or tissues as an effective therapy for a wide range of diseases and conditions such as nerve damage, lung damage, heart damage, etc. ProtoKinetix’ role here is the protection of these cells before, during and after the procedure. 

..Under the terms of the original INSA commission, ProtoKinetix paid for the proof of concept in exchange for the worldwide exclusive rights to the family of AFGP molecules. Subsequently, ProtoKinetix has conducted extensive testing on cell preservation and anti-inflammation resulting in substantial data allowing the Company to file patents. To date, the patents have been granted for the United States, Europe and Canada. 

..In 2014, PKTX filed for a series of new patents based on results generated by the University of Alberta trials. These are brand new applications protected by worldwide provisional patents. 
The Company has completed a series of mechanism of action studies, showing how the molecule achieves its effect of inhibiting inflammation and protecting cells from premature death. This data will enable PKTX to more clearly identify the optimal therapeutic uses for disease. 

..Stem cell research has demonstrated major benefits of using AAGP™ during the following stages: 
1.      Freeze/thaw recovery (cryopreservation) 
2.      Primary differentiation 
3.      Migration to progenitor status (precursor cells) 
4.      Transplantation 
5.      Engraftment 
6.      Protection against anti-rejection drugs



   ***ProtoKinetix Completes Sale of Exclusive Rights for AAGP™ Blood PreservationApplications
                                                                                      March 5, 2014

...ProtoKinetix (PKTX) (www.protokinetix.com) has announced the sale of one of the numerous cell protection applications that prove to significantly increase the shelf life of delicate cells and organs by the addition of AAGP™. The purchaser, Intrepid Innovations Corporation, is a wholly owned subsidiary of Umbra Applied Technologies Group (UATG) and has been funded to address the world-wide demand for blood product storage, and platelet preservation. 

Intrepid is completing this transaction with a combination of cash and securities totaling $2,500,000 USD to PKTX. This acquisition will enable Intrepid to complement their blood bag delivery system and further satisfy the growing domestic and international requirement for blood product trauma treatment. 


                                                                                                                              
                      ***ProtoKinetix Sells Exclusive Rights to One of the Numerous AAGP™ Applications Numerous AAGP™                                                                            April 1^st, 2013

...ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) has entered into the sale of exclusive rights to use it's AAGP™ molecule in all blood and blood platelet preservation applications. These rights have been sold to Intrepid Innovations Corporation for $2,500,000 USD after their extensive review of the AAGP™ molecule's ability to extend blood and blood platelet shelf life.

Intrepid Medical Technologies is a wholly own subsidiary of Intrepid Innovations Corporation that has been specifically funded to address the worldwide need for blood and blood platelet storage and preservation. Intrepid Medical (www.intrepidmedical.net) will be headed up by Mr. Tom Snyder. Tom is a graduate of Princeton University and Harvard Business School. Mr. Snyder brings financial and entrepreneurial experience to Intrepid Medical and has experience in blood diagnostics and therapeutics with Hyland Laboratories and Fenwal divisions of Baxter International.

This Agreement will serve as a blueprint for the commercialization of the numerous AAGP™ applications. The partnering format gives ProtoKinetix the flexibility to structure the sale of application rights to almost any qualified partner. This approach minimizes the cash requirement for product development and the fastest possible entry into the market.

About Intrepid
Intrepid Innovations Corporation is a diversified operation that has acquired, licensed or is developing a wide range of Intellectual Property Rights that offer the opportunity to integrate and commercialize these innovations on a global basis. These proprietary technologies range from wind power generation, oil and natural gas production, wood waste by-products to medical waste disposal and blood preservation.

About ProtoKinetix                
ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

 
 ***ProtoKinetix Forms Joint Venture Partnership to Launch a Dermatitis Therapeutic Product for the Skin Care Industry
                                                              April 27, 2011

...ProtoKinetix (OTCBB:PKTX.ob - News) (www.protokinetix.com), is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market. Over the last 23-years Imaginative Research Associates, Inc. has successfully partnered with several large pharmaceutical dermatology and cosmetic companies and has licensed out patents and know-how to launch many leading products in the skin care arena. Naomi Vishnupad, Ph.D., is the President and COO of this Massachusetts based firm and has over 10-years of experience in the pharmaceutical industry in all areas of drug development. She has held positions in both big pharma, such as Wyeth Pharmaceuticals and Bristol-Myers Squibb, and small biotech companies. Naomi holds a Ph.D. and M.S. in immunology and a B.S. in biology.

Upon completion of this formulation, the Joint Venture will be able to offer a topical preparation to specifically address skin conditions caused by inflammation. Conditions such as dermatitis, psoriasis and eczema are often treated with applications of corticosteroids or immune modulators, both of which carry inherent, long term health risks. ProtoKinetix' AAGP™ has consistently demonstrated powerful anti-inflammatory properties without toxic side effects. The formulation and development of this therapeutic product line will offer hope for an effective prescription and over the counter preparations to combat these chronic inflammation causing diseases, while eliminating potential risks from many of the current front line treatments. 
 

ProtoKinetix Receives Excellent Results from the University of British Columbia Eye Inflammation Study
                                                        September 21 - 2011

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), is pleased to announce that it has received excellent results from the eye inflammation study conducted by UBC (University of British Columbia). The tests conducted by Dr. Gregory-Evans MD, PhD, FRCS, FRCOphth, were designed to determine whether the powerful anti-inflammatory AAGP™ molecule could be successfully delivered to inflamed areas throughout the eye. The result demonstrated that AAGP™ penetrates through the extremely protective barriers of the eye without side effects.

ProtoKinetix has proven the ability of AAGP™ to protect human cells against inflammation causing agents. There are many forms of eye inflammation that are typically treated with an aggressive course of corticosteroids. Due, in part, to the short effective life of topical steroids, current treatments involve the application on an hourly basis. These powerful drugs can lead to numerous sight threatening complications.

Dr. Gregory-Evans, a professor of Ophthalmology and Leadership Chair in Macular Research, concludes that AAGP™ penetrates the eye when topically applied as a twice a day or four times a day regimen. AAGP™ can be detected within the cornea and ciliary body. Drug was also seen to appear in retinal tissue, most convincingly when a four times a day regimen was used.

These results represent a major step in the development of a potent, non-steroidal, anti-inflammatory drug.


                                 Italian Laboratory Expands ProtoKinetix' Market for AAGP™
                                                          December 07 - 2011
 

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) is pleased to announce results from Areta International laboratory in Italy. These results show dramatic increases in the production of monoclonal antibodies when AAGP™ is incorporated into the production cycle. Monoclonal antibodies are one of the fastest growing sectors of the pharmaceutical industry. This market is presently over $50-billion USD per year and growing rapidly. As a therapeutic, monoclonal antibodies do not cause the same side-effects of chemotherapy and radiation treatment.

Since the Company continues to focus on the anti-inflammation applications of AAGP™, they intend to partner the monoclonal antibody development to pharmaceutical laboratories. Monoclonal antibodies have proven themselves to be highly effective therapies and diagnostics, in a growing list of diseases. Access to this class of drug is extremely restricted, due to the prohibitive cost. In order for monoclonal antibodies to be universally available, the cost has to be aggressively reduced.

Initial results from these tests demonstrate a 300% to 500% increase in monoclonal antibody production in the presence of AAGP™. This significant increase in yield, will result in major cost reductions for the treatment of cardio vascular disease, auto-immune disorders, leukemia, transplant rejection, cancer as well as numerous diagnostics.

                                                     
                                            $$$$$$$$ Protokinetix's Daily Chart $$$$$$$$   
                                                             http://schrts.co/yYCnMAQn